Ero1a-KO Mouse
一般名
Ero1a-KO
製品ID
S-KO-10193
背景情報
C57BL/6JCya
系統ID
KOCMP-50527-Ero1a-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Ero1a-KO Mouse（カタログ番号S-KO-10193）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Ero1a-KO
系統ID
KOCMP-50527-Ero1a-B6J-VA
遺伝子名
製品ID
S-KO-10193
遺伝子別名
Ero1l, ERO1-L
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 14
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000022378
NCBIトランスクリプトID
NM_015774
ターゲット領域
Exon 2~8
有効領域の大きさ
~8.5 kb
遺伝子研究の概要
Ablation of ERO1A in tumor cells incites anti-tumor T cell immunity, promotes the efficacy of aPD-1, and induces lethal unfolded protein responses in tumor cells undergoing ER stress, enhancing anti-tumor immunity via immunogenic cell death [1]. In EGFR-mutated non-small cell lung cancer, ablating ERO1A expression affects clonogenicity, tumor sphere formation, and response to Osimertinib [2]. In SEPN1-related myopathy, ERO1A knockout in a mouse background of SEPN1 loss blunts ER stress and improves multiple MAM functions, reversing diaphragmatic weakness [3]. In Drosophila, genetic suppression or pharmacological inhibition of ERO1A homolog ERO1L provides neuroprotection under ER stress and ameliorates UBQLN2-ALS phenotypes [4]. In pancreatic ductal adenocarcinoma, inhibition of ERO1a improves monocyte infiltration and differentiation into dendritic cells [5]. In breast cancer, suppression of microglial ERO1a alleviates inflammation and enhances rehabilitative training efficacy post-ischemic stroke [6]. Small molecule-mediated inhibition of ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment [8]. Cordycepin reduces ERO1A expression, inhibiting lipid metabolism and metastasis in cholangiocarcinoma [9].
In conclusion, ERO1A plays a crucial role in protein folding and redox regulation within the ER. Its ablation or inhibition in various model systems has revealed its significance in cancer, myopathy, neurodegenerative diseases, and stroke-related conditions. These model-based studies, especially gene knockout experiments, have provided insights into the potential of targeting ERO1A for therapeutic intervention in multiple disease areas.
References:
1. Liu, Lihui, Li, Sini, Qu, Yan, Ma, Zixiao, Wang, Jie. 2023. Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. In Cell reports. Medicine, 4, 101206. doi:10.1016/j.xcrm.2023.101206. https://pubmed.ncbi.nlm.nih.gov/37769655/
2. Voronkova, M A, Johnson, B, Gandhi, N, Halmos, B, Hazlehurst, L A. 2024. ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer. In NPJ precision oncology, 8, 250. doi:10.1038/s41698-024-00736-1. https://pubmed.ncbi.nlm.nih.gov/39496753/
3. Germani, Serena, Van Ho, Andrew Tri, Cherubini, Alessandro, Ferreiro, Ana, Zito, Ester. 2024. SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA. In Cell reports. Medicine, 5, 101439. doi:10.1016/j.xcrm.2024.101439. https://pubmed.ncbi.nlm.nih.gov/38402623/
4. Yeewa, Ranchana, Sangphukieo, Apiwat, Jantaree, Phatcharida, Lo Piccolo, Luca, Jantrapirom, Salinee. 2024. ERO1A inhibition mitigates neuronal ER stress and ameliorates UBQLN2ALS phenotypes in Drosophila melanogaster. In Progress in neurobiology, 242, 102674. doi:10.1016/j.pneurobio.2024.102674. https://pubmed.ncbi.nlm.nih.gov/39395630/
5. Tay, Apple Hui Min, Cinotti, Riccardo, Sze, Newman Sui Kwan, Lundqvist, Andreas. 2023. Inhibition of ERO1a and IDO1 improves dendritic cell infiltration into pancreatic ductal adenocarcinoma. In Frontiers in immunology, 14, 1264012. doi:10.3389/fimmu.2023.1264012. https://pubmed.ncbi.nlm.nih.gov/38187398/
6. Ren, Jing, Lv, Yuan, Tian, Qiuyan, Feng, Xing, Ding, Xin. 2023. Suppression of Microglial ERO1a Alleviates Inflammation and Enhances the Efficacy of Rehabilitative Training After Ischemic Stroke. In Molecular neurobiology, 60, 4429-4441. doi:10.1007/s12035-023-03333-8. https://pubmed.ncbi.nlm.nih.gov/37100971/
7. Shergalis, Andrea G, Hu, Shuai, Bankhead, Armand, Neamati, Nouri. 2020. Role of the ERO1-PDI interaction in oxidative protein folding and disease. In Pharmacology & therapeutics, 210, 107525. doi:10.1016/j.pharmthera.2020.107525. https://pubmed.ncbi.nlm.nih.gov/32201313/
8. Varone, Ersilia, Retini, Michele, Cherubini, Alessandro, Cantoni, Orazio, Zito, Ester. 2025. Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment. In Cell death & disease, 16, 105. doi:10.1038/s41419-025-07426-1. https://pubmed.ncbi.nlm.nih.gov/39962052/
9. Zhou, Xuebing, Li, Yuan, Yang, Chunyu, Peng, Bosen, Ren, Xiangshan. 2023. Cordycepin reprogramming lipid metabolism to block metastasis and EMT via ERO1A/mTOR/SREBP1 axis in cholangiocarcinoma. In Life sciences, 327, 121698. doi:10.1016/j.lfs.2023.121698. https://pubmed.ncbi.nlm.nih.gov/37080351/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。